The Filing Desk

GoodRx

GDRX · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

GDRX · Last close · November 19, 2026
$3.02
Value GoodRx yourself

GoodRx's revenue rose 0.6% to $797 million in fiscal 2025. Its operating margin was 11.0%, up from 8.3% a year earlier. Free cash flow was $164 million, down 10.0%. It paid out $216 million in dividends and buybacks, 132% of free cash flow. The diluted share count fell 9.0%.

GoodRx Holdings, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001809519-26-000031 Updated
Revenue
$797M
0.6%
Operating margin
11.0%
2.7 pts
Net income
$30M
85.7%
Free cash flow
$164M
10.0%
Return on capital
5.8%
1.3 pts
Market cap
$1.1B
Nov 19 close
P/E
75.5x
On $0.04 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What GoodRx does

GoodRx runs apps and websites that show Americans what their prescription drugs cost at nearby pharmacies and give them discount codes to pay less. The prices are free to see and can be used at nearly every retail pharmacy in the United States, by people with or without insurance. It also offers paid subscriptions, Gold and RxSmartSaver+, with lower prices at some pharmacies, and telehealth visits through GoodRx Care.

Most of the discounted prices come from pharmacy benefit managers (PBMs), the companies that negotiate drug prices for insurers and employers. When a customer fills a prescription with a GoodRx code, the PBM pays GoodRx a share or a fixed fee, and it keeps paying on refills. In 2025, revenue from these prescription transactions fell $33.5 million, partly because Monthly Active Consumers dropped 14% amid pharmacy store closures. Pharma direct, which advertises drug makers' savings programs for brand-name medicines, grew 41%. Subscriptions are the third line.

GoodRx says it competes mainly with other prescription savings companies and with firms that serve drug makers. In February 2026 the government launched TrumpRx, a site offering drug makers' discounts directly to consumers, and GoodRx works with drug makers that list prices there. It had 697 employees at the end of 2025, all full time.

Its biggest risks, as it describes them

  • A small number of PBMs supply many of the discounted prices it shows, so losing or changing those contracts would cut revenue.
  • Much of its revenue comes from transactions at pharmacy chains, which are closing stores.
  • Government drug pricing programs and new direct-to-consumer sites could change how people look for drug discounts.
  • Failing to persuade people to use its platform when buying medicines, or to keep them coming back.
  • A few large stockholders hold much of the voting power, which limits other shareholders' say.
From GoodRx's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2018 to 2025, earnings per share fell 4.0% a year and net income 5.1% a year, as new shares raised the share count by 202% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments941757672448262
Debt incl. finance leases674667656500495
Net debt (negative means net cash)−267−90−1652233
Net debt to EBITDA−5.6x−1.6x−0.2x0.4x1.4x
Debt to equity0.8x0.8x0.9x0.7x0.8x
Interest coverage0.6x0.1x−0.5x1.2x2.0x
Current ratio13.4x12.1x7.1x5.3x2.6x
Quick ratio13.4x12.1x7.1x5.3x2.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project GoodRx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought GoodRx shares on the open market, and 2 insiders sold $9.7 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 26, 2026Francisco Partners Iv-A L.p.10% ownerSold1,296,177$3.50$4.5 millionForm 4
Aug 25, 2026Francisco Partners Iv-A L.p.10% ownerSold127,273$3.44$437,819Form 4
Aug 24, 2026Francisco Partners Iv-A L.p.10% ownerSold143,594$3.46$496,835Form 4
Aug 21, 2026Francisco Partners GP IV Management Ltd10% ownerSold274,717$3.50$961,510Form 4
Aug 20, 2026Francisco Partners GP IV Management Ltd10% ownerSold447,259$3.52$1.6 millionForm 4
Aug 19, 2026Francisco Partners GP IV Management Ltd10% ownerSold471,975$3.53$1.7 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 87 of 86 of 8
Rule of 4016.2%28.7%21.2%
Altman Z''0.960.61−0.18
Accruals ratio−9.2%−11.2%−9.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio roseFailFailFail
Share count didn't risePassPassPass
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score5 of 87 of 86 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put GoodRx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
GoodRxFY250.6%11.0%20.6%5.8%1.4x6
ClaritevFY253.7%3.0%−1.3%0.5%9.7x5Compare
DoximityFY2613.1%33.3%50.6%91.3%−3.3x4Compare
Hinge HealthFY2550.6%−92.9%29.0%———Compare
WaystarFY2516.5%22.7%25.8%3.5%3.6x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue250388551745767750792797
Revenue growth—55.6%41.9%35.4%2.8%−2.1%5.6%0.6%
Gross profit————————
Research and development442962126143136124121
Operating income77140−276132−276688
Net income4466−294−25−33−91630
Diluted EPS (US$)0.120.18−1.07−0.06−0.08−0.020.040.09
Diluted shares (millions)118231275410413410392357
Cash flow
Cash from operations4583131179147138184168
Capital expenditure112154114
Free cash flow4482111174143137183164
Dividends paid1,3460000000
Share buybacks0000102104159216
Acquisitions031561401570043
Stock-based compensation243971601201059977
Balance sheet at fiscal year end
Cash and short-term investments3526969941757672448262
Debt incl. finance leases—671681674667656500495
Total assets—3871,4701,6081,6051,5891,3881,404
Total liabilities—737759776790827663788
Shareholders' equity−1,162−1,088711832815762725616
Margins and ratios
Gross margin————————
Operating margin31.0%36.0%−50.1%1.8%0.2%−3.6%8.3%11.0%
Net margin17.6%17.0%−53.3%−3.4%−4.3%−1.2%2.1%3.8%
Free cash flow margin17.8%21.1%20.1%23.4%18.6%18.3%23.1%20.6%
Rule of 40 (growth + FCF margin)—76.7%62.0%58.7%21.5%16.2%28.7%21.2%
Return on capital———2.1%0.2%−2.9%4.5%5.8%
Return on equity———−3.3%−4.0%−1.1%2.2%4.5%
Return on assets——−31.6%−1.6%−2.0%−0.6%1.1%2.2%
Net debt to EBITDA—4.2x—−5.6x−1.6x−0.2x0.4x1.4x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: GoodRx's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with GoodRx.